A MINI REVIEW ON PROPERTIES, MECHANISM OF ACTION, PHARMACOKINETIC AND PHARMACODYNAMICS AND ANALYTICAL METHODS OF CARIPRAZINE

Authors

  • ALANKAR SHRIVASTAVA Department of Pharmaceutical Quality Assurance, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad-Meerut Road, Ghaziabad 201206 https://orcid.org/0000-0003-3284-0445
  • RADHIKA AGGARWAL Department of Pharmaceutical Quality Assurance, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad-Meerut Road, Ghaziabad 201206
  • RISHI PRATAP SINGH IIHMR University, Prabhu Dayal Marg, Near Sanganer Airport, Maruti Nagar, Jaipur, Rajasthan 302029
  • RAKHI KHABIYA Acropolis Institute of Pharmaceutical Education & Research, Indore 453771, India

DOI:

https://doi.org/10.22159/ijap.2023v15i1.46651

Keywords:

Method validation, properties, pharmacodynamics, pharmacokinetics, analytical methods, green analytical method

Abstract

Cariprazine (CPZ) being a “D2/D3 receptor partial agonist” is used for schizophrenia treatment. CPZ illustrate different functional study at “dopamine receptors depending on the assay system”. This study elaborate review summarizes the structure–activity relationship (SAR), Mechanism of action (MOA), pharmacokinetics, pharmacodynamics and analytical methods published. CPZ was found to be more effective than risperidone. It was analogus with a remarkably longer time to deteriorate than inactive drug in a long-term, phase III,-deteriorate prevention study. This study elaborate the activating and solemn or sedative properties of first-line oral second generation antipsychotics by explore the rates of adverse effect in product labelling for the indications of schizophrenia and ancillary treatment of major depressive disorder (MDD). The common adverse events reported were extrapyramidal disorder, insomnia, dizziness, solemn, anxiety, vomiting and constipation in “fixed dose study of tested 1.5, 3.0, and 4.5 mg/day”. The presented review explains about biological properties, pharmacokinetics, pharmacodynamics, and analytical methods of CPZ.

Downloads

Download data is not yet available.

References

Carpenter WT Jr, Buchanan RW. Schizophrenia. N Engl J Med. 1994 Mar 10;330(10):681-90. doi: 10.1056/NEJM199403103301006. PMID: 8107719.

Sawa A, Snyder SH. Schizophrenia: diverse approaches to a complex disease. Science. 2002 Apr 26;296(5568):692-5. doi: 10.1126/science.1070532. PMID: 11976442.

Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine Alterations in Schizophrenia: An Updated Review. Front Psychiatry. 2019;10:892. DOI: 10.3389/fpsyt.2019.00892.

Ventriglio A, Gentile A, Bonfitto I, Stella E, Mari M, Steardo L, Bellomo A. Suicide in the Early Stage of Schizophrenia. Front Psychiatry. 2016;7:116. doi: 10.3389/fpsyt.2016.00116. PMID: 27445872; PMCID: PMC4921745.

Pompili M, Giordano G, Luciano M, Lamis DA, Del Vecchio V, Serafini G, Sampogna G, Erbuto D, Falkai P, Fiorillo A. Unmet Needs in Schizophrenia. CNS Neurol Disord Drug Targets. 2017;16(8):870-884. doi: 10.2174/1871527316666170803143927. PMID: 28782490..

Maroney M. An update on current treatment strategies and emerging agents for the management of schizophrenia. Am J Manag Care. 2020 Mar;26(3 Suppl):S55-S61. doi: 10.37765/ajmc.2020.43012. PMID: 32282175.

Hoff AL, Kremen WS. Neuropsychology in schizophrenia: an update. Curr Opin Psychiatry. March 2003;16(2):149-155.

Thaker GK, Carpenter WT Jr. Advances in schizophrenia. Nat Med. 2001;7(6):667-71. DOI: 10.1038/89040.

Lee HJ, Choi BH, Choi JS, Hahn SJ. Effects of cariprazine on hERG 1A and hERG 1A/3.1 potassium channels. Eur J Pharmacol. 2019 Jul 5;854:92-100. DOI: 10.1016/j.ejphar.2019.04.006.

Yamada Y, Matsumoto M, Iijima K, Sumiyoshi T. Specificity and Continuity of Schizophrenia and Bipolar Disorder: Relation to Biomarkers. Curr Pharm Des. 2020;26(2):191-200. doi: 10.2174/1381612825666191216153508. PMID: 31840595; PMCID: PMC7403693.

Marder S, Fleischhacker WW, Earley W, Lu K, Zhong Y, Németh G, Laszlovszky I, Szalai E, Durgam S. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies. Eur Neuropsychopharmacol. 2019;29(1):127-136. doi: 10.1016/j.euroneuro.2018.10.008.

Callaly E, Walder K, Morris G, Maes M, Debnath M, Berk M. Mitochondrial dysfunction in the pathophysiology of bipolar disorder: effects of pharmacotherapy. Mini Rev Med Chem. 2015;15(5):355-65. doi: 10.2174/1389557515666150324122026. PMID: 25807948.

Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci. 2008;10(2):165-79. DOI: 10.31887/DCNS.2008.10.2/evieta.

Firoza M, Groisman JI, Alda M, Turecki G. Pharmacogenetics of Bipolar Disorder, Curr. Pharmacogenomics 2003; 1(4):269-276. doi: https://dx.doi.org/10.2174/1570160033476214.

National Institute of Mental Health. [Internet]. Bipolar Disorder. [Cited 2022 Sept 09]. Available from: https://www.nimh.nih.gov/health/topics/bipolar-disorder.

DelBello MP, Adler CM, Cerullo MA, Fleck DE, Strakowski SM. Bipolar Disorder, Ed(s): Larry R. Squire, Encyclopedia of Neuroscience, Academic Press, 2009; 201-207. doi: https://doi.org/10.1016/B978-008045046-9.00493-9.

Sachs GS, Greenberg WM, Starace A, Lu K, Ruth A, Laszlovszky I, Németh G, Durgam S. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disord. 2015;174:296-302. doi: 10.1016/j.jad.2014.11.018.

National Center for Biotechnology Information. [Internet] PubChem Compound Summary for CID 11154555, Cariprazine. [Cited 2022 Apr 15]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Cariprazine.

McCormack PL. Cariprazine: First Global Approval. Drugs. 2015 Nov;75(17):2035-43. doi: 10.1007/s40265-015-0494-7.

Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in Bipolar Depression and Mania: State of the Art. CNS Neurol Disord Drug Targets. 2018;17(10):723-727. doi: 10.2174/1871527317666180828120256. PMID: 30152291.

De Berardis D, Orsolini L, Iasevoli F, Prinzivalli E, de Bartolomeis A, Serroni N, Mazza M, Valchera A, Fornaro M, Vecchiotti R, Carano A, Sepede G, Vellante F, Matarazzo I, Pompili M, Perna G, Conti C, Segura-García C, Martinotti G, Di Giannantonio M. The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders. Curr Pharm Des. 2016;22(33):5144-5162. doi: 10.2174/1381612822666160701084447.

Gedeon R. [Internet] Cariprazine is well tolerated in the early stage of schizophrenia and has a positive effect on engagement compared to another antipsychotic. [Cited 2021, Apr 13]. Available from: http://www.prnewswire.com/news-releases/gedeon-richter-cariprazine-is-well-tolerated-in-the-early-stage-of-schizophrenia-and-has-a-positive-effect-on-engagement-compared-to-another-antipsychotic-301266936.html

Simon R, Maximilian G. Cariprazine, Experiences from a naturalistic treatment setting. Nervenheilkunde 2020; 39(04): 238-241. DOI: 10.1055/a-0988-2039.

Agai-Csongor E, Domány G, Nógrádi K, Galambos J, Vágó I, Keserű GM, Greiner I, Laszlovszky I, Gere A, Schmidt E, Kiss B, Vastag M, Tihanyi K, Sághy K, Laszy J, Gyertyán I, Zájer-Balázs M, Gémesi L, Kapás M, Szombathelyi Z. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012 May 15;22(10):3437-40. doi: 10.1016/j.bmcl.2012.03.104.

Findlay LJ, El-Mallakh PL, El-Mallakh RS. Cariprazine for the Treatment of Bipolar Disorder. Perspect Psychiatr Care. 2017 Jul;53(3):148-155. doi: 10.1111/ppc.12150.

Jiali Ye, Kaihang Liu, Xinbo Zhou, Jianming Gu, Xiurong Hu. Crystal Structures and Thermodynamic Properties of New Atypical Antipsychotic Cariprazine and Its Hydrochloride. Crystallogr Rep. 2018;63, 930–936. doi: https://doi.org/10.1134/S1063774518060147.

Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925-35. doi: 10.1016/j.neuint.2011.07.002.

Mazza M, Marano G, Traversi G, Carocci V, Romano B, Janiri L. Cariprazine in Bipolar Depression and Mania: State of the Art. CNS Neurol Disord Drug Targets. 2018;17(10):723-727. doi: 10.2174/1871527317666180828120256.

Shrivastava A, Mittal A. A Mini Review on Characteristics and Analytical Methods of Otilonium Bromide. Crit Rev Anal Chem. 2022;52(7):1717-1725. doi: 10.1080/10408347.2021.1913983. PMID: 34039224.

Shrivastava A., Sharma, S., Kaurav, M., & Sharma, A. Characteristics and analytical methods of mannitol: an update. Int J Appl Pharm. 2021;13(5): 20–32. doi: https://doi.org/10.22159/ijap.2021v13i5.42068.

Shrivastava A. Characteristics and Analytical Methods of Novel PDE5 Inhibitor Avanafil: An Update. Hacet. Univ. J. Fac. Pharm. 2022;42(2): 134-147. doi: 10.52794/hujpharm.1017182

Robert P. Plain Radiographic Imaging, Editor(s): Dennis M. Marchiori, Clinical Imaging (Third Edition), Mosby, 2014;1-43. doi: https://doi.org/10.1016/B978-0-323-08495-6.00001-4.

Lewis ML Heat transfer mechanisms. In Woodhead Publishing Series in Food Science, Technology and Nutrition, Physical Properties of Foods and Food Processing Systems, Woodhead Publishing, 1996; 246-291. doi: https://doi.org/10.1533/9781845698423.246.

Structure Elucidation in Organic Chemistry: The Search for the Right Tools, First Edition. Edited by María-Magdalena Cid and Jorge Bravo. 2015 Wiley-VCH Verlag GmbH & Co. KGaA. doi: https://doi.org/10.1002/9783527664610.ch1.

Shrivastava A. UV Spectrophotometry: Applications in Adulteration Analysis of Drugs, Frontiers in Drug Safety Adulteration Analysis of Some Foods and Drugs. 2018; 1: 80. doi: https://doi.org/10.2174/9781681086750118010008.

Mészáros GP, Agai-Csongor E, Kapás M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-RGH-188 in human plasma and urine. J Pharm Biomed Anal. 2008;48(2):388-97. doi: 10.1016/j.jpba.2007.12.016.

Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59(6):925-35. DOI: 10.1016/j.neuint.2011.07.002.

Tóth M, Varrone A, Steiger C, Laszlovszky I, Horváth A, Kiss B, Gyertyán I, Adham N, Halldin C, Gulyás B. Brain uptake and distribution of the dopamine D3 /D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates. Synapse. 2013;67(5):258-64. doi: 10.1002/syn.21631.

Ablordeppey S, Ofori E. Antipsychotic Agents. Ed: Donald J. Abraham and Michael Myers. Burger’s Medicinal Chemistry, Drug Discovery and Development, Eighth Edition. 2021 John Wiley & Sons, Inc. doi: 10.1002/0471266949.bmc103.pub3.

Ribeiro ELA, de Mendonça LT, Vieira MEB, Storpirtis S, Aguiar PM. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews, Eur. J. Clin. Pharmacol. 2018;74:1215e1233. doi: https://doi.org/10.1007/s00228-018-2498-1

Scarff JR. Cariprazine for schizophrenia and bipolar disorder. Innov Clin Neurosci 2016; 13: 49-52.

Qassim S, Boura F, Al-hariri Y. Public knowledge and attitude toward depression and schizophrenia: findings from quantitative study in UAE. Asian J Pharm Clin Res, 2018;11(7):402-6. doi:10.22159/ajpcr.2018.v11i7.26160.

Arya A, Sindhwani G, Kadian R. Neurotransmitter and brain parts involved in schizophrenia. Asian J Pharm Clin Res, 2018;11(6):4-11. doi:10.22159/ajpcr.2018.v11i6.24557.

Published

21-11-2022

How to Cite

SHRIVASTAVA, A., AGGARWAL, R., SINGH, R. P., & KHABIYA, R. (2022). A MINI REVIEW ON PROPERTIES, MECHANISM OF ACTION, PHARMACOKINETIC AND PHARMACODYNAMICS AND ANALYTICAL METHODS OF CARIPRAZINE. International Journal of Applied Pharmaceutics, 15(1). https://doi.org/10.22159/ijap.2023v15i1.46651

Issue

Section

Review Article(s)